More specifically, the presence of a BRAF V600E mutation was not associated with CRC survival, even among cases diagnosed with distant metastatic disease, and the presence of known oncogenic mutations in KRAS was only modestly associated with poorer survival (Supplementary Data 2). This evidence concerns the gene KRAS and colorectal carcinoma.